Teasing Apart Multiple Biologic Failure in Psoriasis, PsA
'Tough-to-treat psoriasis remains a challenge despite newer therapies ... Why do we still have this sub-population of patients who seem to be refractory?'
Source: medscape.com
Stay updated with breaking news from Christophert Ritchlin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
'Tough-to-treat psoriasis remains a challenge despite newer therapies ... Why do we still have this sub-population of patients who seem to be refractory?'
At week 52, patients in the bimekizumab cohort demonstrated sustained clinical responses, which were consistent with results reported at week 16.
Differing patient selection criteria and other biases may be why results from a new study contradict those from three prior studies, suggesting the need for prospective studies.